AbbVie Inc said on Wednesday that all patients in a late-stage study showed a sustained response to its cocktail of hepatitis C treatments, currently sold in the U.S. as Viekira Pak.
↧
AbbVie hepatitis C cocktail succeeds in late-stage study
↧